![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 18
Zeitschriftenartikel
Kruger, S. F.; Lohneis, A.; Abendroth, A.; Berger, A. W.; Ettrich, T. J.; Waidmann, O.; Kapp, M.; Steiner, B.; Kumbrink, J.; Reischer, A.; Haas, M.; Westphalen, C. B.; Zhang, D.; Miller-Phillips, L.; Burger, P. J.; Kobold, S.; Werner, J.; Subklewe, M.; Bergwelt-Baildon, M. von; Kunzmann, V.; Seufferlein, T.; Siveke, J. T.; Sinn, M.; Heinemann, V.; Ormanns, S. und Boeck, S.
(2022):
Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study.
In: ESMO Open, Bd. 7, Nr. 1, 100388
Hayden, P. J.; Roddie, C.; Bader, P.; Basak, G. W.; Bonig, H.; Bonini, C.; Chabannon, C.; Ciceri, F.; Corbacioglu, S.; Ellard, R.; Sanchez-Guijo, F.; Jaeger, U.; Hildebrandt, M.; Hudecek, M.; Kersten, M. J.; Koehl, U.; Kuball, J.; Mielke, S.; Mohty, M.; Murray, J.; Nagler, A.; Rees, J.; Rioufol, C.; Saccardi, R.; Snowden, J. A.; Styczynski, J.; Subklewe, M.; Thieblemont, C.; Topp, M.; Ispizua, A. U.; Chen, D.; Vrhovac, R.; Gribben, J. G.; Kroeger, N.; Einsele, H. und Yakoub-Agha, I
(2022):
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).
In: Annals of Oncology, Bd. 33, Nr. 3: S. 259-275
Haubner, S.; Perna, F.; Koehnke, T.; Schmidt, C.; Berman, S.; Augsberger, C.; Schnorfeil, F. M.; Krupka, C.; Lichtenegger, F. S.; Liu, X.; Kerbs, P.; Schneider, S.; Metzeler, K. H.; Spiekermann, K.; Hiddemann, W.; Greif, P. A.; Herold, T.; Sadelain, M. und Subklewe, M.
(2019):
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.
In: Leukemia, Bd. 33, Nr. 1: S. 64-74
Reiter, K.; Polzer, H.; Krupka, C.; Maiser, A.; Vick, B.; Rothenberg-Thurley, M.; Metzeler, K. H.; Doerfel, D.; Salih, H. R.; Jung, G.; Noessner, E.; Jeremias, I.; Hiddemann, W.; Leonhardt, H.; Spiekermann, K.; Subklewe, M. und Greif, P. A.
(2018):
Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.
In: Leukemia, Bd. 32, Nr. 2: S. 313-322
Prassek, V. V.; Rothenberg-Thurley, M.; Sauerland, M. C.; Amler, S.; Görlich, D.; Herold, T.; Janke, H.; Schneider, S.; Subklewe, M.; Krug, U.; Faldum, A.; Berdel, W.; Wörmann, B.; Bräss, J.; Spiekermann, K.; Hiddemann, W. und Metzeler, K.
(2017):
AML patients aged >= 75 years enrolled into AMLCG trials: do genetic alterations impact clinical outcome in very old, intensively treated patients?
In: Oncology Research and Treatment, Bd. 40: S. 29
Costanzi, M.; Krupka, C.; Kischel, R.; Kufer, P.; Köhnke, T.; Spiekermann, K.; Hiddemann, W. und Subklewe, M.
(2017):
Secretion Of Soluble Factors By AML Cells Influence CD33/CD3 BITE (R) Antibody Mediated Cytotoxicity And T-Cell Proliferation.
In: Haematologica, Bd. 102: S. 357-358
Pachzelt, L.; Krupka, C.; Kischel, R.; Kufer, P.; Köhnke, T.; Polzer, H.; Spiekermann, K.; Hiddemann, W. und Subklewe, M.
(2017):
Costimulation Increases Intracellular Signalling In Bite (R) Antibody Construct Mediated T-Cell Activation.
In: Haematologica, Bd. 102: S. 361
Prassek, V.; Rothenberg-Thurley, M.; Sauerland, M. C.; Amler, S.; Görlich, D.; Herold, T.; Janke, H.; Schneider, S.; Subklewe, M.; Krug, U.; Faldum, A.; Berdel, W. E.; Wörmann, B.; Braess, J.; Hiddemann, W.; Spiekermann, K. und Metzeler, K. H.
(2017):
AML patients aged >= 75 years enrolled into AMLCG trials: do genetic alterations impact clinical outcome in very old, intensively treated patients?
In: Haematologica, Bd. 102: S. 209-210
Bücklein, V. L.; Krause, S.; Ölschlägel, U.; Köhnke, T.; Schnorfeil, F.; Völkl, S.; Rieger, M. A.; Berg, T.; Hoffmann, J.; Brendel, C.; Hiddemann, W.; Subklewe, M. und Bonin, M. von
(2017):
Defining minimal residual disease by flow cytometry in acute myeloid leukemia: the HARMONIZE initiative.
In: Oncology Research and Treatment, Bd. 40: S. 43
Herold, Tobias; Jurinovic, V.; Metzeler, K. H.; Batcha, A. M. N.; Bamopoulos, S. A.; Rothenberg-Thurley, M.; Ksienzyk, B.; Hartmann, L.; Greif, P. A.; Phillippou-Massier, J.; Krebs, S.; Blum, H.; Amler, S.; Schneider, S.; Konstandin, N.; Sauerland, M. C.; Berdel, W. E.; Wörmann, B. J.; Subklewe, M.; Fiegl, M.; Bohlander, S. K.; Braess, J.; Hiddemann, W.; Mansmann, Ulrich und Spiekermann, K.
(2017):
Prediction of Primary Refractory Acute Myeloid Leukemia.
In: Annals of Hematology, Bd. 96:
S25-S25
Lichtenegger, F. S.; Deiser, K.; Rothe, M.; Krupka, C.; Schnorfeil, F. M.; Augsberger, C.; Köhnke, T.; Bücklein, V; Altmann, T.; Moosmann, A.; Brüggemann, M.; Heemskerk, M. H. M.; Wagner, B.; Hiddemann, W.; Bigalke, I; Kvalheim, G. und Subklewe, M.
(2016):
Induction of antigen-specific T-cell responses through dendritic cell vaccination in AML: results of a phase I/II trial and ex vivo enhancement by checkpoint blockade.
In: Oncology Research and Treatment, Bd. 39: S. 135
Rothenberg-Thurley, M.; Amler, S.; Görlich, D.; Sauerland, M. C.; Schneider, S.; Konstandin, N. P.; Schaaf, S.; Nazeer Batcha, A. M.; Bräundl, K.; Ksienzyk, B.; Zellmaier, E.; Mansmann, Ulrich; Fiegl, M.; Subklewe, M.; Bohlander, S. K.; Faldum, A.; Hiddemann, W.; Spiekermann, K.; Braess, J. und Metzeler, K. H.
(2016):
Persistence of driver mutations during complete remission associates with shorter survival and contributes to the inferior outcomes of elderly patients with acute myeloid leukemia.
In: Oncology Research and Treatment, Bd. 39: S. 110-111
Krupka, C.; Lindl, B.; Platzer, J.; Brauneck, F.; Kischel, R.; Kufer, P.; Lichtenegger, F. S.; Köhnke, T.; Rothe, M.; Deiser, K.; Augsberger, C.; Altmann, T.; Spiekermann, K.; Hiddemann, W. und Subklewe, M.
(2016):
Influence of cytoreductive and immunmodulatory drugs on antibody-based approaches in AML.
In: Oncology Research and Treatment, Bd. 39: S. 84-85
Issels, R.; Büclein, V.; Kampmann, E.; Knösel, T.; Nössner, E.; Subklewe, M. und Lindner, L.
(2016):
Dissecting the role of tumor-infiltrating lymphocytes (TIL) in patients with high-risk soft-tissue sarcoma (STS) receiving neo-adjuvant chemotherapy (NAC) with regional hyperthermia (RHT).
In: Annals of Oncology, Bd. 27
Wagner, B.; Karagianni, M.; Buhmann, R.; Scheffler, A.; Wichmann, C.; Subklewe, M. und Wittmann, G.
(2016):
Two leukapheresis systems for manufacturing dendritic cell vaccine for postremission therapy in aml.
In: Cytotherapy, Bd. 18, Nr. 6:
S66-S66
Rothenberg-Thurley, M.; Amler, S.; Goerlich, D.; Sauerland, M. C.; Schneider, S.; Konstandin, N. P.; Schaaf, S.; Batcha, A. M. Nazeer; Bräundl, K.; Ksienzyk, B.; Zellmeier, E.; Mansmann, Ulrich; Fiegl, M.; Subklewe, M.; Bohlander, S. K.; Faldum, A.; Hiddemann, W.; Spiekermann, K.; Braess, J. und Metzeler, K. H.
(2016):
Persistence of driver mutations during complete remission associates with shorter survival and contributes to the inferior outcomes of elderly patients with acute myeloid leukemia.
In: Haematologica, Bd. 101: S. 23
Krupka, C.; Kufer, P.; Kischel, R.; Zugmaier, G.; Lichtenegger, F. S.; Köhnke, T.; Vick, B.; Jeremias, I.; Metzeler, K. H.; Altmann, T.; Schneider, S.; Fiegl, M.; Spiekermann, K.; Bauerle, P. A.; Hiddemann, W.; Riethmüller, G. und Subklewe, M.
(2016):
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.
In: Leukemia, Bd. 30, Nr. 2: S. 484-491
Dufour, A.; Schneider, F.; Hoster, Eva; Benthaus, T.; Ksienzyk, Bianka; Schneider, S.; Kakadia, P. M.; Sauerland, M. C.; Berdel, W. E.; Büchner, T.; Wörmann, Bernhard; Braess, J.; Subklewe, M.; Hiddemann, Wolfgang; Bohlander, Stefan K. und Spiekermann, Karsten
(2012):
Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
In: Annals of Hematology, Bd. 91, Nr. 7: S. 1051-1063